NEW YORK (GenomeWeb) – Biodesix announced today that it has chosen Progenetics to market and distribute its liquid biopsy tests in Israel.

Under the terms of the agreement, Tel Aviv-based Progenetics will market and distribute Biodesix's GeneStrat and VeriStrat tests, which are available for clinical use in patients with non-small cell lung cancer (NSCLS).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.